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Abstract 
Review on CHST11, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: C4ST, C4ST-1, C4ST1, 
HSA269537 
HGNC (Hugo): CHST11 
Location: 12q23.3 
Local order: Centromere - NFYB - TXNRD1 - 
CHST11 - SLC41A2 - ALDH1L2. 
 
DNA/RNA 
Description 
The CHST11 gene spans 305 kb on chromosome 
12q23.3. 
Transcription 
The CHST11 gene contains one 5' non-coding exon 
and three coding exons and is transcribed into a 5.7 
kb mRNA.  
Transcription of CHST11 has been shown to be 
positively regulated by signaling through 
transforming growth factor-beta (TGFβ) pathways 
(Klüppel et al., 2002).  
 
Genomic organization of the CHST11 locus on chromosome 12q23.3, encompassing nucleotides 104850692 to 105155792. 
Orientation (5' to 3') of CHST11, and neighbouring genes TXNRD1, SCL41A2, and ALDH1L2 are indicated by arrowheads. cen: 
centromere; qter: telomere of q-arm. Adapted from USCS Genome Browser, hg19 (November 2013). 
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Schematic illustration of the protein structure of CHST11 with known motifs indicated. CHST11 contains a transmembrane 
domain (TMD) for anchorage in the Golgi membrane (encoded by exon III), and a large luminal catalytic domain harboring a 
sulfotransferase domain, which contains a 5'-phosphosulfate site (PSB), a 3' phosphate binding site (PB), as well as four C-
terminal N-glycosylation sites (N1-N4) (all encoded by exon IV). 
 
 
Using a bioinformatical approach, conserved long-
range cis-regulatory modules were identified in the 
CHST11 locus. 
Luciferase reporter assays identified a functional 
CHST11 promoter, as well as a number of cis-
regulatory modules able to positively and 
negatively regulate CHST11 expression in a TGFβ-
dependent as well as -independent manner (Willis 
et al., 2009). 
Protein 
Description 
The CHST11 protein contains 352 amino acids, and 
has an approximate molecular mass of 43 kDa. 
CHST11 is a single pass type II membrane-bound 
protein (Klüppel, 2010).  
CHST11 protein contains a transmembrane domain 
(TMD) for anchorage in the Golgi mebrane, a 5' 
phosposulfate binding site (PSB), a 3' phosphate 
binding site (PB), required for binding of the 
phosphate donor PAPS and transfer of sulfate 
groups, and four N-linked glycosylation sites (N1 to 
N4) in the C-terminal end of the protein. 
Expression 
CHST11 has a highly specific temporal and spatial 
expression pattern during mouse embryogenesis, 
and has been detected in notocord, heart valves and 
myocardium, apical ectodermal ridge during limb 
generation, neural tube, hair follicles, kidney, and 
proliferating chondrocytes in the cartilage growth 
plate during skeletal development (Klüppel et al., 
2002; Klüppel et al., 2005).  
In adult tissues, CHST11 has been reported to be 
widely expressed, including in spleen, thymus, 
bone marrow, peripheral blood leukocytes, lymph 
node, heart, brain, lung and placenta (Habuchi and 
Miyashita, 1982; Hiraoka et al., 2000; Okuda et al., 
2000; Yamauchi et al., 2000). 
Localisation 
CHST11 is a single pass type II membrane-bound 
protein localized to the Golgi (Klüppel, 2010). 
However, CHST11 was initially identified as a 
protein secreted from chondrocytes and 
chondrosarcoma cells (Habuchi et al., 1991; 
Yamauchi et al., 1999). 
Function 
Role in carbohydrate metabolism: 
CHST11 catalyzes the transfer of sulfate from the 
universal intracellular sulfate donor PAPS (3'-
Phosphoadenosine 5'-phosphosulfate) to the C4 
position of the glycosaminoglycan chondroitin, 
generating chondroitin-4-sulfate (C4S) and 
adenosine 3',5'-bisphosphate (Habuchi, 2000; 
Klüppel, 2010). Through a subsequent CHST11-
independent enzymatic sulfation reaction, C4S can 
be transformed into the double-sulfated chondroitin 
sulfate-E (CS-E) (Habuchi, 2000; Klüppel, 2010). 
Different chondroitin sulfation forms have been 
shown to have distinct biological functions. 
CHST11 has also been shown to positively regulate 
chondroitin sulfate chain elongation (Anggraeni et 
al., 2011). N-glycosylation of CHST11 is required 
for its enzymatic function and heat stability (Yusa 
et al., 2005). 
Role in cartilage development and osteoarthritis 
(OA): 
Mouse CHST11 has been shown to be required for 
cartilage growth plate morphogenesis (Klüppel et 
al., 2005). Loss of CHST11 caused 
chondrodysplasia with severely shortened long 
bones, caused by shortened and thickened cartilage 
growth plates with disorganized and hypo-cellular 
cartilage growth plates with fibrillated ECM and an 
overall loss of chondroitin sulfate. Increased 
apoptosis of mutant chondrocytes was observed, 
and TGFbeta and BMP signaling was disturbed in 
mutant growth plates (Klüppel et al., 2005). Many 
of these cartilage deficiencies are characteristic of 
the degenerative alterations observed in OA, a 
degenerative disease characterized by loss of matrix 
GAGs and cartilage integrity. Increased CHST11 
expression has been observed in OA (Zeggini et al., 
2012). Combined, these data suggest a requirement 
for tightly controlled regulation of CHST11 
expression in the development and maintenance of 
healthy cartilage. 
Role in HSV infection: 
Herpes simplex virus (HSV) envelope 
glycoproteins utilize cell-surface GAGs to 
efficiently bind to and infect host cells. The gC 
HSV envelope protein has been suggested to bind 
cell-surface CS-E-proteoglycans with high affinity, 
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and treatment with exogenous CS-E could potently 
inhibit HSV infectivity, thus identifying CS-E 
chains of cell-surface proteoglycans as key 
receptors for HSV entry into a host cell. Deficiency 
in CHST11 expression leads to drastically reduced 
susceptibility to HSV infection in L-cell fibroblasts, 
presumably through the absence of CHST11-
mediated CS-E synthesis (Uyama et al., 2006). 
Role in malaria: 
Malaria is caused by the parasites of the species 
Plasmodium, and is transmitted through infected 
mosquitos. High affinity adherence of P. 
falciparum-infected erythrocytes to endothelial cells 
is mediated by the CHST11 product C4S on 
endothelial cell-surface proteoglycans (Rogerson et 
al., 1995; Cooke et al., 1996; Pouvelle et al., 1997; 
Beeson et al., 1998). 
Role in Costello syndrome: 
Costello syndrome is a pediatric genetic disorder 
linked to oncogenic germline mutations in the 
HRAS gene (Gripp, 2005; Quezada and Gripp, 
2007; Rauen, 2007; Gripp and Lin, 2012). The 
disease is characterized by multiple developmental 
abnormalities as well as predisposition to 
malignancies (White et al., 2005; Quezada and 
Gripp, 2007; Rauen et al., 2008). Reduction in 
CHST11 mRNA and protein expression, as well as 
loss of C4S has been identified in primary 
fibroblasts derived from Costello syndrome patients 
(Hinek et al., 2005; Klüppel et al., 2012). 
Oncogenic HRAS in normal fibroblasts can repress 
CHST11 expression, while interference with 
oncogenic HRAS signaling in these cells elevated 
CHST11 expression, thus identifying CHST11 as a 
negatively regulated target gene of HRAS signaling 
(Klüppel et al., 2012). Forced expression of 
CHST11 in Costello fibroblasts rescued the 
proliferation and elastogenesis defects associated 
with oncogenic HRAS signaling in these cells 
(Klüppel et al., 2012). These results indicate that 
reduced CHST11 expression and a subsequent 
chondroitin sulfation imbalance mediate the effects 
of oncogenic HRAS signaling in the pathogenesis 
of Costello syndrome. 
Role in cancer: 
Changes in CS levels and chondroitin sulfation 
balance have been described during tumor 
progression (Ricciardelli et al., 1997; Suwiwat et 
al., 2004; Theocharis et al., 2006; Sakko et al., 
2008; Teng et al., 2008; Svensson et al., 2011; 
Vallen et al., 2012). Experimental elimination of 
chondroitin sulfate in orthotopic breast cancer 
mouse models lead to increased metastasis, 
demonstrating a critical role of chondroitin epitopes 
in tumor progression in vivo (Prinz et al., 2011). 
The CHST11 gene was highly expressed in 
aggressive breast cancer cells, but significantly less 
so in less aggressive breast cancer cell lines 
(Cooney et al., 2011). Moreover, a positive 
correlation was observed between the expression 
levels of CHST11 and P-selectin-mediated 
adherence of breast cancer cells to endothelial cells 
(Cooney et al., 2011). Increased expression of the 
CHST11 gene has been observed in multiple 
myeloma (Bret et al., 2009). One case report of a 
patient with B-cell chronic lymphocytic leukemia 
(B-CLL), a chromosomal translocation with 
breakpoints in the IGH locus on chromosome 14, 
and the CHST11 locus on chromosome 12 
[t(12;14)(q23;q32)] was identified. The 
translocation breakpoint mapped to intron 2 of the 
CHST11 locus, and resulted in the expression of 
two truncated forms of CHST11 (Schmidt et al., 
2004). 
Role in Wnt-β-catenin signaling: 
Studies were performed in mutant sog9 L-cell 
fibroblasts, which lack the expression of both EXT1 
(Extosis-1, required for heparan sulfate 
biosynthesis) and CHST11 genes (Nadanaka et al., 
2008). Mutant cells had a significant decrease in 
Wnt3a-stimulated β-catenin accumulation, which 
could be rescued by stably expressing CHST11, but 
not EXT-1 (Nadanaka et al., 2008). In addition, this 
study showed that the specific chondroitin sulfate 
form CS-E, but not the other chondroitin sulfate 
forms, was able to bind Wnt3a ligand with high 
affinity. Addition of CS-E to normal L-cells 
reduced β-catenin levels, much like what was seen 
in the sog9 mutant L-cells lacking CHST11 
expression (Nadanaka et al., 2008).  
Together, this data suggested that the CHST11, 
through its ability to produce CS-E containing 
proteoglycans, might play a role in the Wnt/β-
catenin signaling pathway.  
The investigators of this study suggested a model in 
which CHST11 expression increases the level of 
CS-E containing proteoglycans, which can then 
bind Wnt3a, and facilitate the binding of Wnt 
ligands to its receptor complex, thus increasing the 
efficiency of ligand-receptor interactions. In a 
follow-up study, Nadanaka et al. (2011) show that 
L-cells stably expressing the Wnt3a ligand had a 
reduction in CHST11 gene expression, and 
subsequently a change in sulfation balance with a 
higher concentration of chondroitin sulfate products 
with low affinity for Wnt3a ligand binding 
(Nadanaka et al., 2011). This allows the Wnt3a 
ligand to freely diffuse across L-cell fibroblast 
cultures. Forced expression of CHST11 was 
suggested to inhibit the diffusion of Wnt3a ligand 
in L-cell fibroblast cultures, because of the increase 
in production of CS-E containing proteoglycans 
(Nadanaka et al., 2011). These and previous studies 
suggested that CHST11 expression is able to inhibit 
Wnt3a diffusion and sustained signaling, but 
CHST11 gene expression is negatively regulated by 
active Wnt/β-catenin signaling (Nadanaka et al., 
2011).  
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CHST11-IgH fusion transcripts generated by a chromosomal translocation t(12;14)(q23;q32) in a patient with B-cell chronic 
lymphocytic leukemia. Fusions I and II retain 3' parts of the CHST11 coding sequence, including the sulfotransferase domain in 
exon IV. Fusion III retains the 5' part of the CHST11 transcript, including non-coding exons I and exon II, which encodes the 
transmembrane domain. Thus, fusions I and II are predicted to lack transmembrane domains, but retain sulfotransferase activity, 
whereas fusion III contains the CHST11 transmembrane domain, but lacks the sulfotransferase domain. The IgH components in 
all fusion transcripts are mainly non-coding sequences; the largest reading frame in the IgH-derived sequences are 36 bp in 
length (Schmidt et al., 2004). Figure adapted and modified from Schmidt et al., 2004. 
 
We reported the identification of the CHST11 
product CS-E as an inhibitor of specific molecular 
and biological outcomes of Wnt3a signaling in 
NIH3T3 fibroblasts (Willis and Klüppel, 2012). 
CS-E could decrease Wnt3a signaling through 
negative regulation of LRP6 receptor activation. 
However, this inhibitory effect of CS-E only 
affected Wnt3a-mediated induction, but not 
repression, of target gene expression (Willis and 
Klüppel, 2012). We went on to identify a critical 
Wnt3a signaling threshold that differentially affects 
target gene induction versus repression. This Wnt3a 
signaling threshold also differentially controlled the 
effects on proliferation and serum starvation-
induced apoptosis (Willis and Klüppel, 2012). 
These data established the feasibility to manipulate 
the chondroitin sulfate biosynthesis machinery, in 
particular CHST11, to selectively inhibit Wnt/β-
catenin transcriptional programs and biological 
outcomes through the exploitation of intrinsic 
signaling thresholds (Willis and Klüppel, 2012). 
Homology 
Homologous genes: CHST12, CHST13. 
Mutations 
Note 
A chromosomal translocation t(12;14)(q23;q32) has 
been described in one patient with B-cell chronic 
lymphocytic leukemia (B-CLL) (Schmidt et al., 
2004). Breakpoints of this have been mapped to the 
IGH locus on chromosome 14, and the CHST11 
locus on chromosome 12 [t(12;14)(q23;q32)] 
(Schmidt et al., 2004). The translocation breakpoint 
mapped to intron 2 of the CHST11 locus, and 
resulted in the expression of three CHST11-IgH 
fusion transcripts (Schmidt et al., 2004).  
It was not determined whether these fusion 
transcripts lead to the expression of truncated 
CHST11 proteins, or whether the expression of the 
observed fusion transcripts might have any 
functional consequences on chondroitin sulfate 
biosynthesis and/or disease development or 
severity. 
Somatic 
This is a somatic mutation in B-CLL cells (Schmidt 
et al., 2004). 
Implicated in 
B-cell chronic lymphocytic leukemia 
(B-CLL) 
Cytogenetics 
Translocation t(12;14)(q23;q32). 
Hybrid/Mutated gene 
This translocation generates a IGH-CHST11 hybrid 
gene, with breakpoints in the IGH locus on 
chromosome 14, and the CHST11 locus on 
chromosome 12. A functional role of this hybrid 
CHST11 (carbohydrate (chondroitin 4) sulfotransferase 11) Klüppel M 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(12) 936 
gene in tumor progression has not been elucidated 
(Schmidt et al., 2004). 
Multiple myeloma 
Note 
Microarray analysis identified increased expression 
of a number genes involved in glycosaminoglycan 
biosynthesis, including CHST11 (Bret et al., 2009). 
The authors hypothesized that heparan sulphate and 
chondroitin sulphate side chains of the proteoglycan 
syndecan-1 play critical roles in mediating the 
biological changes from memory B cells to 
malignant plasma cells (Bret et al., 2009). 
Breast cancer 
Note 
The CHST11 gene is highly expressed in 
aggressive breast cancer cells, but significantly less 
so in less aggressive breast cancer cell lines 
(Cooney et al., 2011). Moreover, a positive 
correlation was observed between the expression 
levels of CHST11 and P-selectin-mediated 
adherence of breast cancer cells to endothelial cells 
(Cooney et al., 2011). 
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